These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21763166)

  • 21. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA; Ismail NS
    Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis.
    Wu Q; Gao Q; Guo H; Li D; Wang J; Gao W; Han C; Li Y; Yang L
    Mol Biosyst; 2013 Mar; 9(3):386-97. PubMed ID: 23354020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
    Park H; Yeom MS; Lee S
    Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
    Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
    Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.
    Yuan M; Luo M; Song Y; Xu Q; Wang X; Cao Y; Bu X; Ren Y; Hu X
    Bioorg Med Chem; 2011 Feb; 19(3):1189-96. PubMed ID: 21237663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3D-QSAR studies of some tetrasubstituted pyrazoles as COX-II inhibitors.
    Gupta GK; Kumar A
    Acta Pol Pharm; 2012; 69(4):763-72. PubMed ID: 22876620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
    Tripathi SK; Muttineni R; Singh SK
    J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular docking and QSAR studies on substituted acyl(thio)urea and thiadiazolo [2,3-alpha] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase.
    Sun J; Cai S; Mei H; Li J; Yan N; Wang Q; Lin Z; Huo D
    Chem Biol Drug Des; 2010 Sep; 76(3):245-54. PubMed ID: 20626407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting kinase selectivity profiles using Free-Wilson QSAR analysis.
    Sciabola S; Stanton RV; Wittkopp S; Wildman S; Moshinsky D; Potluri S; Xi H
    J Chem Inf Model; 2008 Sep; 48(9):1851-67. PubMed ID: 18717582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
    Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
    Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.
    Yuan H; Liu H; Tai W; Wang F; Zhang Y; Yao S; Ran T; Lu S; Ke Z; Xiong X; Xu J; Chen Y; Lu T
    SAR QSAR Environ Res; 2013 Oct; 24(10):795-817. PubMed ID: 23941641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives.
    Faris A; Hadni H; Ibrahim IM; Elhallaoui M
    J Biomol Struct Dyn; 2024 Jun; 42(9):4817-4833. PubMed ID: 37338041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploration of a binding mode of benzothiazol-2-yl acetonitrile pyrimidine core based derivatives as potent c-Jun N-terminal kinase-3 inhibitors and 3D-QSAR analyses.
    Sharma P; Ghoshal N
    J Chem Inf Model; 2006; 46(4):1763-74. PubMed ID: 16859308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insight into the structural features of pyrazolopyrimidine- and pyrazolopyridine-based B-Raf(V600E) kinase inhibitors by computational explorations.
    Li Y; Han C; Wang J; Yang Y; Zhang J; Zhang S; Yang L
    Chem Biol Drug Des; 2014 Jun; 83(6):643-55. PubMed ID: 24373283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atom and receptor based 3D QSAR models for generating new conformations from pyrazolopyrimidine as IL-2 inducible tyrosine kinase inhibitors.
    Ul-Haq Z; Effendi JS; Ashraf S; Bkhaitan MM
    J Mol Graph Model; 2017 Jun; 74():379-395. PubMed ID: 28499271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyrimidine-based pyrazoles as cyclin-dependent kinase 2 inhibitors: Design, synthesis, and biological evaluation.
    Vekariya MK; Vekariya RH; Brahmkshatriya PS; Shah NK
    Chem Biol Drug Des; 2018 Sep; 92(3):1683-1691. PubMed ID: 29767460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
    Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
    J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.
    Gao L; Zu M; Wu S; Liu AL; Du GH
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5964-70. PubMed ID: 21843936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.